Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Enrolling by invitation 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1Genitourinary 1

Conditions

Prostatic Neoplasms, Castration-Resistant 1Neoplasms 1Myelodysplastic Syndromes 1Lymphoma, Non-Hodgkin 1Leukemia, Myeloid, Acute 1Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

Specimen Handling 602pembrolizumab 557Magnetic Resonance Spectroscopy 527Carboplatin 422Cyclophosphamide 370Cisplatin 369Biopsy 349Paclitaxel 304Gemcitabine 299Nivolumab 298Radiotherapy 256Bevacizumab 232Dexamethasone 207fludarabine 203Docetaxel 185durvalumab 177atezolizumab 172Oxaliplatin 170Fluorouracil 166venetoclax 164Rituximab 163Pemetrexed 161Doxorubicin 157Radiation 155Capecitabine 155Radiosurgery 145Etoposide 137Leucovorin 133Ipilimumab 132Lenalidomide 129

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × JNJ-64264681 × 90 days × Clear all
NCT06788509 2026-06-05

A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring

Janssen Research & Development, LLC

Phase 1 Enrolling by invitation
120 enrolled
GenitourinaryLymphoidMyeloidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes, Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute, Prostatic Neoplasms, Castration-Resistant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡